ArticlePloS one2025
Developing and assessing MyTBCompanion - A tri-lingual integrated video observed therapy app for tuberculosis patient management in Malaysia and Indonesia.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLimited studies have developed a mobile phone-based application that supports Asynchronous Video Observed Therapy (A-VOT) for Tuberculosis (TB) program. This study aimed to design, develop, and assess MyTBCompanion, a mobile phone-based digital health intervention to support A-VOT for TB management and care among low-income patients in Malaysia and Indonesia.
methodsMyTBCompanion was designed and developed under a partnership involving experts in information technology, respiratory disease, and linguistics. Pre and Post-test surveys were done to assess feedback on the existing TB strategies (Direct Observed Therapy (DOT) and/or VOT) and the usability of the tested A-VOT strategy using MyTBCompanion. We collected data on the patient's age, education level, current treatment strategy, and statements measuring four MyTBCompanion components: Engagement (how interesting, customizable, interactive and well-targeted to an audience an app is), Functionality (ease of use, app design, navigation), Aesthetic (the graphic design, overall visual appeal, color scheme, and stylistic consistency) and Information (content accuracy and relevance). The Mann-Whitney U test was performed for group comparisons, with results considered significant at p < 0.05.
resultsIn total, 49 patients with TB were recruited from Malaysia (n = 29) and Indonesia (n = 20). Most participants in both countries were 20-40 years old. Indonesian participants mainly had tertiary education (11/20, 55.0%), whereas most had secondary education level in Malaysia (17/29, 58.6%). Most Malaysian participants (19/29, 65.5%) were using VOT through WhatsApp, with fewer (10/29, 34.5%) using DOT. All participants from Indonesia (20/20, 100%) were using the DOT strategy. Overall, compared to the existing strategies, a higher mean agreement score was observed for MyTBCompanion, with Information scoring the highest agreement (4.57/5.0), followed by Engagement (4.53/5.0), Functionality (4.51/5.0) and Aesthetic (4.49/5.0).
conclusionFindings suggest an overall good agreement on the usability of A-VOT strategy using MyTBCompanion in terms of engagement, functionality, information and aesthetics, with many indicating their willingness to recommend it to others, marking an encouraging milestone in the app's development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.